Want to see HK:6160 full AI Analyst Report?
6160 Stock Chart & Stats
HK$199.20
HK$0.50(0.25%)
At close: 4:00 PM EDT
HK$199.20
HK$0.50(0.25%)
Day’s Range― - ―
52-Week RangeHK$153.00 - HK$229.40
Previous CloseN/A
Volume2.70M
Average Volume (3M)5.08M
Market Cap
HK$327.79B
Enterprise ValueHK$231.34K
Total Cash (Recent Filing)HK$5.10B
Total Debt (Recent Filing)HK$1.14B
Price to Earnings (P/E)60.7
Beta0.85
Next Earnings
Nov 05, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding1,427,230,000
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$271.54Price Target Upside36.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)4.36
Revenue Forecast (FY)HK$52.77B
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Returned ProfitabilityVery high gross margins and a return to positive EBIT and net margins indicate a structurally advantaged cost base or differentiated product mix. This supports durable profitability, funding for R&D and commercialization, and provides operating leverage that can sustain earnings over the next 2–6 months.
Strong Free Cash Flow GenerationConsistent, growing free cash flow improves financial flexibility and reduces reliance on external funding. FCF roughly aligned with earnings (about 85% of net income) signals decent earnings quality and gives the company capacity to invest, repay debt, or pursue strategic initiatives over the medium term.
Manageable Leverage And Positive ROEModerate leverage combined with a positive return on equity suggests capital structure that balances growth funding and risk. A built-up equity base provides a buffer versus shocks and supports sustainable capital allocation choices, preserving resilience across economic cycles.
Bears Say
Slowing Revenue GrowthDecelerating top-line expansion reduces the margin for error in biotech where ongoing R&D and commercialization costs are elevated. Slower revenue momentum makes sustaining current profitability more dependent on cost control or product uptake and raises the bar to prove durable growth over coming quarters.
Recent History Of Negative Cash FlowsPrior years' material cash outflows highlight execution and cash-conversion risk. Even with current positive FCF, the business must demonstrate sustained cash generation to avoid repeating past funding stress, which could force dilution or debt-funded growth if cash performance deteriorates.
Upward Drift In LeverageAn increasing debt load reduces financial flexibility and raises vulnerability to earnings volatility or higher rates. If leverage continues to climb while growth softens, the company may face constrained investment capacity or higher financing costs, pressuring margins and strategic options.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$153.00 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$327.79B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Aug 05, 2026. The company reported HK$1.237 earnings per share for the quarter, beating the consensus estimate of HK$1.001 by HK$0.236.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 1.15.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,427,230,000 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$1.237 in its last earnings report, beating expectations of HK$1.001. Following the earnings report the stock price went up 2.634%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$271.54 (36.31% Upside)
HK$271.54 (36.31% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
47.56%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
6160 Stock 12 Month Forecast
Average Price Target
HK$271.54
▲(36.31% Upside)
Technical Analysis
Innovent Biologics
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―